MX2016015551A - Composicion farmaceutica que comprende compuesto de pirazina-carboxamida como ingrediente activo. - Google Patents
Composicion farmaceutica que comprende compuesto de pirazina-carboxamida como ingrediente activo.Info
- Publication number
- MX2016015551A MX2016015551A MX2016015551A MX2016015551A MX2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibiting effect
- cancers
- jak3
- itk
- btk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
Se proporciona una composición farmacéutica para tratar el cáncer en el cual están implicadas una o más quinasas BTK, JAK3 e ITK. Los presentes inventores estudiaron compuestos que tienen un efecto inhibidor de BTK, un efecto inhibidor de JAK3 y un efecto inhibidor de ITK, y confirmaron que un compuesto de pirazina carboxamida específico tiene el efecto inhibidor de BTK, el efecto inhibidor de JAK3 y el efecto inhibidor de ITK y que una composición farmacéutica que comprende el compuesto como ingrediente activo tiene un efecto terapéutico sobre el cáncer en el cual está implicada una o más quinasas de BTK, JAK3 e ITK, en otro aspecto, cáncer en el cual se sobreexpresa o activa la BTK, en otro aspecto, cáncer en el cual se activa la señal del receptor de células B, aún en otro aspecto, un cáncer en el cual se activa-muta o activa la JAK3 y aún en otro aspecto, el cáncer en el cual se activa la ITK, completando de este modo la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014109952 | 2014-05-28 | ||
PCT/JP2015/065154 WO2015182628A1 (ja) | 2014-05-28 | 2015-05-27 | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016015551A true MX2016015551A (es) | 2017-03-23 |
Family
ID=54698952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016015551A MX2016015551A (es) | 2014-05-28 | 2015-05-27 | Composicion farmaceutica que comprende compuesto de pirazina-carboxamida como ingrediente activo. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20170196859A1 (es) |
EP (1) | EP3150206A1 (es) |
JP (1) | JPWO2015182628A1 (es) |
KR (1) | KR20170005820A (es) |
CN (1) | CN106456636A (es) |
AU (1) | AU2015266552A1 (es) |
CA (1) | CA2949028A1 (es) |
EA (1) | EA201692479A1 (es) |
IL (1) | IL249010A0 (es) |
MA (1) | MA39908A (es) |
MX (1) | MX2016015551A (es) |
PH (1) | PH12016502313A1 (es) |
SG (1) | SG11201609837WA (es) |
TW (1) | TW201625254A (es) |
WO (1) | WO2015182628A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3290036A4 (en) * | 2015-04-27 | 2019-01-02 | Astellas Pharma Inc. | Stabilized pharmaceutical composition |
JP2019014653A (ja) * | 2015-11-27 | 2019-01-31 | アステラス製薬株式会社 | がん免疫を介したがん治療方法 |
US20190282569A1 (en) * | 2016-10-26 | 2019-09-19 | Astellas Pharma Inc. | Stable pharmaceutical composition |
WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110025224A (ko) * | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
NZ627709A (en) * | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
RS55704B1 (sr) * | 2012-01-17 | 2017-07-31 | Astellas Pharma Inc | Jedinjenje pirazin karboksamida |
-
2015
- 2015-05-27 CN CN201580026409.3A patent/CN106456636A/zh active Pending
- 2015-05-27 MA MA039908A patent/MA39908A/fr unknown
- 2015-05-27 MX MX2016015551A patent/MX2016015551A/es unknown
- 2015-05-27 EA EA201692479A patent/EA201692479A1/ru unknown
- 2015-05-27 AU AU2015266552A patent/AU2015266552A1/en not_active Abandoned
- 2015-05-27 WO PCT/JP2015/065154 patent/WO2015182628A1/ja active Application Filing
- 2015-05-27 US US15/314,364 patent/US20170196859A1/en not_active Abandoned
- 2015-05-27 EP EP15799603.4A patent/EP3150206A1/en not_active Withdrawn
- 2015-05-27 SG SG11201609837WA patent/SG11201609837WA/en unknown
- 2015-05-27 KR KR1020167033075A patent/KR20170005820A/ko unknown
- 2015-05-27 TW TW104116974A patent/TW201625254A/zh unknown
- 2015-05-27 JP JP2016523519A patent/JPWO2015182628A1/ja active Pending
- 2015-05-27 CA CA2949028A patent/CA2949028A1/en not_active Abandoned
-
2016
- 2016-11-16 IL IL249010A patent/IL249010A0/en unknown
- 2016-11-21 PH PH12016502313A patent/PH12016502313A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12016502313A1 (en) | 2017-02-13 |
TW201625254A (zh) | 2016-07-16 |
SG11201609837WA (en) | 2016-12-29 |
US20170196859A1 (en) | 2017-07-13 |
MA39908A (fr) | 2015-12-03 |
IL249010A0 (en) | 2017-01-31 |
CA2949028A1 (en) | 2015-12-03 |
WO2015182628A1 (ja) | 2015-12-03 |
EA201692479A1 (ru) | 2017-03-31 |
AU2015266552A1 (en) | 2016-12-01 |
EP3150206A1 (en) | 2017-04-05 |
CN106456636A (zh) | 2017-02-22 |
KR20170005820A (ko) | 2017-01-16 |
JPWO2015182628A1 (ja) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
PH12018500899A1 (en) | Compositions and methods for inhibiting arginase activity | |
EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
PH12016501578A1 (en) | Pharmaceutical compounds | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
PH12016501962A1 (en) | Macrocyclic pyridine derivatives | |
PH12016501963A1 (en) | Macrocyclic pyrimidine derivatives | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
PH12016501527B1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
PH12016502313A1 (en) | Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient | |
PT3279210T (pt) | Péptido com atividade anticancerígena, composição farmacêutica e composição de suplementos alimentares para prevenção e tratamento do cancro, ambos os quais contêm o mesmo ingrediente ativo | |
PH12017501334A1 (en) | 3,5-diaminopyrazole kinase inhibitors | |
MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
MX2017007648A (es) | Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo. |